drugset / Trial / NCT00175643

Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses

NCT00175643

Non-randomizedSingle-groupOpen-labelTreatment

Summary

It is believed that imiquimod 5% cream has the potential to be an effective treatment for actinic keratoses. The purpose of this study is to evaluate the duration of the effect of topical imiquimod 5% topical cream for the treatment of actinic keratoses.

Timeline

Start
2005-02
Primary completion
Completion
2005-11

Publications

  • Background (1.) Somani N, Rivers JK. Imiquimod 5% cream for the treatment of actinic keratoses. Skin Therapy Lett 2005;10(2):1-6. (2.) Rivers JK. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses. Skin Therapy Lett 2004;9(1):1-3. (3.) Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002;146 (4.) Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997;133(10):1239-42.

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 5 % Topical

Indications